Encore Biotechnology, S.A. de C.V. – Trademark Portfolio
Entity Type: 03
Encore Biotechnology, S.A. de C.V. holds 3 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 2 filings in this category. The portfolio also extends into Class 5 (Pharmaceuticals) across 2 Nice Classification classes. Currently, 3 trademarks are registered. Notable registered marks include HAKKI and LIVENTIA. The owner is based in Mexico City.
Laplace 34-4 Col. Anzures Miguel Hidalgo
Mexico City 11590 , MX
Showing of trademarks Trademarks
Trademark Classifications
Encore Biotechnology, S.A. de C.V.'s trademark portfolio spans 2 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Encore Biotechnology, S.A. de C.V. have?
Encore Biotechnology, S.A. de C.V. has 3 U.S. trademarks filed with the USPTO. Of these, 3 registered.
What trademark classes does Encore Biotechnology, S.A. de C.V. file in?
Encore Biotechnology, S.A. de C.V. files trademarks across 2 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Encore Biotechnology, S.A. de C.V.'s most well-known trademarks?
Encore Biotechnology, S.A. de C.V.'s registered trademark portfolio includes well-known marks such as HAKKI and LIVENTIA. These are among 3 currently registered trademarks in the portfolio.
What is Encore Biotechnology, S.A. de C.V.'s trademark registration success rate?
Encore Biotechnology, S.A. de C.V. has a 100% trademark registration rate, with 3 out of 3 resolved applications resulting in successful registration. Currently, 0 applications are pending review.